Shanghai‑listed Mabwell Bioscience (SHA: 688062) announced today that its anti‑TMPRSS6 monoclonal antibody 9MW3011 (R&D code 9MW3011/DISC‑3405) has entered the first‑patient, first‑dose cohort of a global Phase II trial. The drug, previously licensed to DISC Medicine, is poised to become the only therapeutic that targets the protease TMPRSS6 in polycythemia vera (PV), a rare myeloproliferative neoplasm.
Why 9MW3011 Matters
| Feature | Detail |
|---|---|
| Mechanism | 9MW3011 blocks TMPRSS6, a key negative regulator of the iron‑homeostasis hormone hepcidin, thereby up‑regulating endogenous hepcidin and restoring physiological iron balance. |
| Clinical Status | • Phase II – first‑patient dose on 24 Sept 2025 • Phase Ib – three ongoing studies in China • FDA Designations – Fast‑Track & Orphan Drug |
| Competitive Edge | Unlike exogenous hepcidin mimetics, 9MW3011 offers a biologically relevant, endogenous‑hepcidin‑driven iron‑regulatory effect that could translate into fewer off‑target effects and better tolerability. |
| Target Population | Patients with polycythemia vera, a disease lacking disease‑modifying therapies and associated with chronic iron overload and thrombosis risk. |
Regulatory & Market Context
- Fast‑Track & Orphan Drug Status – Accelerated review pathways from the U.S. FDA underscore the unmet need for PV therapies and the potential for a rapid market entrance.
- Shanghai Market – With three Phase Ib trials already active in China, Mabwell is positioned to secure early commercial traction in a 1.4‑billion‑person market that is increasingly receptive to precision oncology and rare‑disease solutions.
- Global Growth – The worldwide PV market is projected to exceed $1.2 billion by 2030, driven by rising prevalence and the search for disease‑modifying agents.
Forward‑Looking Statements
Mabwell cautions that the Phase II results will inform dose‑selection and safety evaluation for a planned Phase III study, and that regulatory milestones are subject to change based on emerging data.-Fineline Info & Tech
